Вредност серумских Тх1/Тх2 цитокина у комбинацији са туморским маркерима у дијагнози ХР-ХПВ-позитивног рака грлића материце
Serum Th1/Th2 cytokines and tumor markers in cervical cancer
Sažetak
Objective: To analyze the value of serum helper T-cell 1 (Th1)/helper T-cell 2 (Th2) cytokines combined with tumor markers in the diagnosis of high-risk human papillomavirus (HR-HPV)-positive cervical cancer.
Methods: Forty-nine patients with HR-HPV-positive cervical cancer admitted to the hospital from January 2020 to June 2024 were selected as the study group, and 49 patients with HR-HPV-positive benign cervical diseases of the same age group admitted to the hospital during the same period were selected as the control group.
The basic data, serum Th1/Th2 cytokines [interleukin (IL)-10, IL-6, interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α)], and tumor markers [squamous cell carcinoma antigen (SCCAg), carbohydrate antigen 199 (CA199) levels and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1)] of the two groups were compared, and the serum Th1/Th2 cytokine levels of patients with different clinicopathological characteristics in the study group were compared. Pearson correlation analysis was used to analyze the correlation between the levels of serum Th1/Th2 cytokines and tumor markers in patients with HR-HPV-positive cervical cancer. A receiver operating characteristic (ROC) curve was drawn to analyze the value of serum Th1/Th2 cytokines and tumor markers in the diagnosis of HR-HPV-positive cervical cancer.
Results: The levels of serum IL-10, IL-6, IFN-Y, TNF-a, SCC-Ag, CA199 and CYFRA21-1 in the study group were greater than those in the control group (P<0.05). The levels of serum IL-10, IL-6, IFN-γ and TNF-α in patients at stages III–IV of the International Federation of Obstetrics and Gynecology (FIGO) in the study group were all greater than those in patients at stages ⅰ–II (P<0.05), and the levels of serum IL-10, IL-6, IFN-γ and TNF-A in patients with a myometrial invasion depth ≥1/2 were all greater than those in patients with a myometrial invasion depth <1/2 (P<0.05). The levels of serum IL-10, IL-6, IFN-Y and TNF-an in patients with HR-HPV-positive cervical cancer were positively correlated with the levels of SCC-Ag, CA199 and CYFRA21-1 (P<0.05). The AUCs of IL-10, IL-6, IFN-Y and TNF-a for the single diagnosis of HR-HPV-positive cervical cancer were 0.809, 0.773, 0.801 and 0.794, respectively, and the AUCs of SCC-Ag, CA199 and CYFRA21-1 for the single diagnosis of HR-HPV-positive cervical cancer were 0.831 and 0, respectively. 728, 0.789. The AUC of the combined diagnosis of HR-HPV-positive cervical cancer by serum IL-10, IL-6, IFN-Y, TNF-a, SCC-Ag, CA199, and CYFRA21-1 was 0.927. The AUC of the combined diagnosis was greater than that of the individual diagnosis of each index (Z=2.116, 2.690, 2).341, 2.565, 1.957, 3.351, 2.631, P=0.034, 0.007, 0.019, 0.010, 0.039, 0.001, 0.009).
Conclusion: The combined detection of serum Th1/Th2 cytokine imbalance (elevated IL-6 and IL-10) and tumor markers (SCC, CA125) can significantly improve the diagnostic accuracy of HR-HPV-positive cervical cancer and provide a high-value serological auxiliary basis for the early identification of cervical cancer progression.
Reference
2.Xu HH, Xie YY, Jun-Gan, Yang Z, Han QY. Dynamic changes of soluble HLA-G and cytokine plasma levels in cervical cancer patients: potential role in cancer progression and immunotherapy. J Cancer Res Clin Oncol. 2023 Jul;149(8):4195-4204.
3.Ha JL, Kaser E, Guan T, Mayberry TG, Smith LA, D'mello K, Bai Q, Wakefield MR, Dong L, Fang Y. Up and away with cervical cancer: IL-29 is a promising cytokine for immunotherapy of cervical cancer due to its powerful upregulation of p18, p27, and TRAILR1. Med Oncol. 2024 Jan 28;41(3):65.
4.Fourie L, Christowitz C, Eksteen C, van der Merwe H, Botha H, Venter C, Engelbrecht AM. Inflammation and thrombotic risk in late-stage cervical cancer: An exploratory study of coagulation and cytokine profiles in a South African cohort. Cytokine. 2024 Dec;184:156782.
5.Yu C, Wang J, Li Y. TRIM8 Promotes Proliferation, Invasion, and Migration of Cervical Cancer Cells by Ubiquitinating and Degrading SOCS1. Biochem Genet. 2024 Jun 25.
6.Saha S, Sultana S, Rahmat R, Akther T, Nessa A, Jahan M. Patterns of Different Cervical Cytokine Expression in High-Risk Human Papillomavirus-Infected Patients With Cervical Cancer and Its Precancerous Lesions. Clin Med Insights Oncol. 2025 Mar 25;19:11795549251316767.
7.Fujii T, Nishio E, Tsukamoto T, Kukimoto I, Iwata A. Performance of an ancillary test for cervical cancer that measures miRNAs and cytokines in serum and cervical mucus. Cancer Sci. 2024 Aug;115(8):2795-2807.
8.Simanullang RH, Situmorang PC, Herlina M, Noradina, Silalahi B, Manurung SS. Histological changes of cervical tumors following Zanthoxylum acanthopodium DC treatment, and its impact on cytokine expression. Saudi J Biol Sci. 2022 Apr;29(4):2706-2718.
9.Ao L, Shi J, Gan J, Yu W, Du H. Effects of dexmedetomidine and ketorolac applied for patient controlled analgesia on the balance of Th1/Th2 and level of VEGF in patients undergoing laparoscopic surgery for cervical cancer: A randomized controlled trial. Oncol Lett. 2024 Jun 17;28(2):379.
10.Yang Y, Zhu J, Feng R, Han M, Chen F, Hu Y. Altered vaginal cervical microbiota diversity contributes to HPV-induced cervical cancer via inflammation regulation. PeerJ. 2024 Jun 12;12:e17415.
11.Molina MA, Steenbergen RDM, Pumpe A, Kenyon AN, Melchers WJG. HPV integration and cervical cancer: a failed evolutionary viral trait. Trends Mol Med. 2024 Sep;30(9):890-902.
12.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852.
13.Bhattacharjee R, Das SS, Biswal SS, Nath A, Das D, Basu A, Malik S, Kumar L, Kar S, Singh SK, Upadhye VJ, Iqbal D, Almojam S, Roychoudhury S, Ojha S, Ruokolainen J, Jha NK, Kesari KK. Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies. Crit Rev Oncol Hematol. 2022 Jun;174:103675.
14.Hernández-Silva CD, Ramírez de Arellano A, Pereira-Suárez AL, Ramírez-López IG. HPV and Cervical Cancer: Molecular and Immunological Aspects, Epidemiology and Effect of Vaccination in Latin American Women. Viruses. 2024 Feb 21;16(3):327.
15.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248.
16.Włoszek E, Krupa K, Skrok E, Budzik MP, Deptała A, Badowska-Kozakiewicz A. HPV and Cervical Cancer-Biology, Prevention, and Treatment Updates. Curr Oncol. 2025 Feb 22;32(3):122.
17.Dorji T, Tshomo U, Gyamtsho S, Tamang ST, Wangmo S, Pongpirul K. Gender-neutral HPV elimination, cervical cancer screening, and treatment: Experience from Bhutan. Int J Gynecol Obstet. 2022 Mar;156(3):425-429.
18.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861.
19.Ueda Y. Epidemiology of cervical cancer and HPV infection in Asia and Oceania. J Obstet Gynecol Res. 2024 Oct;50 Suppl 1:31-41.
20.Kombe AJK, Zoa-Assoumou S, Bounda GA, Nsole-Biteghe FA, Jin T, Zouré AA. Advances in Etiopathological Role and Control of HPV in Cervical Cancer Oncogenesis. Front Biosci (Landmark Ed). 2023 Oct 19;28(10):245.
21.Ni H, Huang C, Ran Z, Li S, Kuang C, Zhang Y, Yuan K. Targeting HPV for the prevention, diagnosis, and treatment of cervical cancer. J Mol Cell Biol. 2025 May 2;16(10):mjae046.
22.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603.
23.Ginindza TG, Forestier M, Almonte M. Cervical cancer screening by visual inspection and HPV testing in Eswatini. Prev Med. 2022 Aug;161:107144.
24.Gu Y, Li T, Zhang M, Chen J, Shen F, Ding J, Zhou G, Hua K. The Display between HPV Infection and Host Immunity in Cervical Cancer. Front Biosci (Landmark Ed). 2024 Dec 24;29(12):426.
25.Sasieni P, Castanon A. HPV vaccination and cervical cancer screening - Authors' reply. Lancet. 2022 May 21;399(10339):1940.
26.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959.
Sva prava zadržana (c) 2025 Xia Cao, Xuemei Zhang, Jingpo Zhang, Xiaodang Zhong, Shanshan Hu
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.